Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of antibody targeted radiotherapy for relapsed low grade non Hodgkin lymphoma
This trial looked into the treatment of low grade non Hodgkin lymphoma (NHL) that had come back after it was first treated.
It used targeted radiotherapy that was given by injecting a monoclonal antibody that carried radiation. The antibody would find NHL cells throughout the body, so the radiation should be carried directly to those cells and the treatment should have fewer side effects.
The monoclonal antibody was called Bexxar (tositumomab).
The aim of the trial was to find out how well this treatment worked for relapsed low grade NHL.
Summary of results
The trial team found that Bexxar works well as treatment for low grade NHL that had come back after it was first treated.
This trial recruited 89 people. Everyone had Bexxar.
Overall the number of people who responded to BEXXAR was 68 out of every 100 (68%). The average time it took for their NHL to come back was just under 2 years. The average length of time people lived after treatment was just over 5 years.
The trial team concluded that people with low grade NHL that had come back after treatment responded well to BEXXAR.
We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Johnson
Coulter Pharmacutical Inc.